Robert Burkes1,2, Andrew Osterburg1, Timothy Hwalek1, Laura Lach2, Ralph J Panos1,2, Michael T Borchers1,2. 1. Division of Pulmonary, Critical Care, and Sleep Medicine, College of Medicine, University of Cincinnati, Cincinnati, Ohio, United States. 2. Department of Veterans Affairs, Cincinnati VA Hospital, Cincinnati, Ohio, United States.
Abstract
BACKGROUND: Cytomegalovirus (CMV) represents an understudied chronic infection, usually contracted early in life, that causes chronic immune system alterations which may contribute to airflow limitations in a cohort of veterans with a high prevalence of smoking. We studied 172 participants at-risk for and with airflow limitation with available CMV serology to assess the relationship between CMV infection and chronic obstructive pulmonary disease (COPD)-related outcomes. METHODS: The study cohort includes 172 veterans who are smokers with or at risk for the development of COPD. Clinical data were obtained by chart abstraction at enrollment. CMV affinity (ever-exposure) and avidity testing (length of exposure) were performed on plasma samples collected at enrollment. Bivariable and multivariable logistic regression was used to determine the relationship between both cytomegalovirus affinity and avidity and odds of prevalent airflow limitation (post-bronchodilator forced expiratory volume in 1 second to forced vital capacity ratio <0.70) at enrollment. In those with airflow limitation (n=84), bivariable and multivariable logistic regression was used to determine relationships between CMV serostatus and reported exacerbations of COPD over 2 years prior to enrollment. RESULTS: Positive CMV serostatus was independently associated with a 136% higher odds of airflow limitation (95% confidence interval 1.11-5.06, P=0.03) at enrollment. Neither CMV affinity nor avidity was associated with COPD exacerbations in the 2 years prior to enrollment. CONCLUSIONS: CMV serostatus is independently associated with airflow limitation in a cohort of veterans who smoke. Investigation into the timing of infection and alterations in cellular immunity caused by chronic CMV infection and smoking-related airways disease-related outcomes is warranted. JCOPDF
BACKGROUND: Cytomegalovirus (CMV) represents an understudied chronic infection, usually contracted early in life, that causes chronic immune system alterations which may contribute to airflow limitations in a cohort of veterans with a high prevalence of smoking. We studied 172 participants at-risk for and with airflow limitation with available CMV serology to assess the relationship between CMV infection and chronic obstructive pulmonary disease (COPD)-related outcomes. METHODS: The study cohort includes 172 veterans who are smokers with or at risk for the development of COPD. Clinical data were obtained by chart abstraction at enrollment. CMV affinity (ever-exposure) and avidity testing (length of exposure) were performed on plasma samples collected at enrollment. Bivariable and multivariable logistic regression was used to determine the relationship between both cytomegalovirus affinity and avidity and odds of prevalent airflow limitation (post-bronchodilator forced expiratory volume in 1 second to forced vital capacity ratio <0.70) at enrollment. In those with airflow limitation (n=84), bivariable and multivariable logistic regression was used to determine relationships between CMV serostatus and reported exacerbations of COPD over 2 years prior to enrollment. RESULTS: Positive CMV serostatus was independently associated with a 136% higher odds of airflow limitation (95% confidence interval 1.11-5.06, P=0.03) at enrollment. Neither CMV affinity nor avidity was associated with COPD exacerbations in the 2 years prior to enrollment. CONCLUSIONS: CMV serostatus is independently associated with airflow limitation in a cohort of veterans who smoke. Investigation into the timing of infection and alterations in cellular immunity caused by chronic CMV infection and smoking-related airways disease-related outcomes is warranted. JCOPDF
Authors: David J Lederer; Scott C Bell; Richard D Branson; James D Chalmers; Rachel Marshall; David M Maslove; David E Ost; Naresh M Punjabi; Michael Schatz; Alan R Smyth; Paul W Stewart; Samy Suissa; Alex A Adjei; Cezmi A Akdis; Élie Azoulay; Jan Bakker; Zuhair K Ballas; Philip G Bardin; Esther Barreiro; Rinaldo Bellomo; Jonathan A Bernstein; Vito Brusasco; Timothy G Buchman; Sudhansu Chokroverty; Nancy A Collop; James D Crapo; Dominic A Fitzgerald; Lauren Hale; Nicholas Hart; Felix J Herth; Theodore J Iwashyna; Gisli Jenkins; Martin Kolb; Guy B Marks; Peter Mazzone; J Randall Moorman; Thomas M Murphy; Terry L Noah; Paul Reynolds; Dieter Riemann; Richard E Russell; Aziz Sheikh; Giovanni Sotgiu; Erik R Swenson; Rhonda Szczesniak; Ronald Szymusiak; Jean-Louis Teboul; Jean-Louis Vincent Journal: Ann Am Thorac Soc Date: 2019-01
Authors: Amanda M Simanek; Jennifer Beam Dowd; Graham Pawelec; David Melzer; Ambarish Dutta; Allison E Aiello Journal: PLoS One Date: 2011-02-17 Impact factor: 3.240
Authors: Matthew Grigsby; Trishul Siddharthan; Muhammad Ah Chowdhury; Ali Siddiquee; Adolfo Rubinstein; Edgardo Sobrino; J Jaime Miranda; Antonio Bernabe-Ortiz; Dewan Alam; William Checkley Journal: Int J Chron Obstruct Pulmon Dis Date: 2016-10-05
Authors: Robert M Burkes; Amanda J Gassett; Agathe S Ceppe; Wayne Anderson; Wanda K O'Neal; Prescott G Woodruff; Jerry A Krishnan; R Graham Barr; MeiLan K Han; Fernando J Martinez; Alejandro P Comellas; Allison A Lambert; Joel D Kaufman; Mark T Dransfield; J Michael Wells; Richard E Kanner; Robert Paine; Eugene R Bleecker; Laura M Paulin; Nadia N Hansel; M Bradley Drummond Journal: Ann Am Thorac Soc Date: 2018-07
Authors: J Michael Wells; Dongqi Xing; Liliana Viera; Robert M Burkes; Yixin Wu; Surya P Bhatt; Mark T Dransfield; David J Couper; Wanda O'Neal; Eric A Hoffman; Amit Gaggar; Igor Barjaktarevic; Jeffrey L Curtis; Wassim W Labaki; Mei Lan K Han; Christine M Freeman; Nirupama Putcha; Thomas Schlange; J Edwin Blalock Journal: Respir Res Date: 2019-11-12